Merck & Co., Inc. (MRK) Files for Global Approval of Pimicotinib After Positive Phase III TGCT Results
Merck & Co., Inc. (NYSE:MRK) is seeking worldwide regulatory approval for its CSF-1R inhibitor pimicotinib following robust Phase III results in tenosynovial giant cell tumour (TGCT). The MANEUVER trial, conducted with Abbisko Therapeutics, showed a 61.9% overall response rate (ORR) by tumour volume score (TVS) after 25 weeks, far surpassing placebo (3.2%). This efficacy outperformed Daiichi Sankyo's Turalio (56% ORR) and was just behind Ono Pharmaceutical's Romvimza (67% ORR), which received FDA approval in February 2025.
Pixabay/Public Domain
Quality of life improvements were notable, with significant gains in range of movement, stiffness, and pain reduction. Importantly, pimicotinib demonstrated a favorable safety profile: while all patients experienced some adverse events, only 4.8% were serious, and there were no signs of liver toxicity, a key differentiator from other therapies.
TGCT, a rare non-cancerous joint tumour, often recurs after surgery, making effective drug options crucial. Merck & Co., Inc. (NYSE:MRK), having secured global rights from Abbisko in March 2025, has filed for approval in China and plans an FDA submission by year-end. Full results will be presented at ASCO 2025 in Chicago.
While we acknowledge the potential of MRK to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than MRK and that has 100x upside potential, check out our report about this
READ NEXT: and
Disclosure: None.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
28 minutes ago
- Yahoo
Public markets primed for US IPO revival despite tariff uncertainty, NYSE President Martin says
By Arasu Kannagi Basil (Reuters) -Intercontinental Exchange-owned NYSE's President Lynn Martin said on Thursday that public markets were ready for well-prepared companies despite tariff unease as easing volatility was setting the stage for a rebound in U.S. IPO activity. Optimism that 2025 would finally be the year for a strong rebound in U.S. IPO market activity has recently been tempered by tariff-driven uncertainty, but the window seems to be opening up again after volatility eased and equities bounced back. "There's been this narrative in the market, particularly for the last two years. It's a bit false that companies can't go public," Martin said at the Piper Sandler Global Exchange & Trading Conference. The companies debuting at this time were public-market ready, she said, highlighting the successful listings of cybersecurity firm Rubrik and social media platform Reddit last year. "They were ready to go. They went, and they've done extraordinarily well," Martin said. Analysts say the IPO market could be in the early stages of a broader pickup, but that sustained stability was needed before the window opens fully. "We expect approximately one or two deals per week in June, ramping up a bit in July after Independence Day, and if all goes well, a full rebound in September, October after the summer lull," said Matt Kennedy, senior strategist at Renaissance Capital, a provider of IPO-focused research and ETFs. NYSE TEXAS The impending launch of the Texas Stock Exchange, backed by Wall Street giants BlackRock and Citadel Securities, is set to heat up the competition in listings markets. The NYSE was following its playbook, talking to its customers about why more of them were moving to Texas, Martin said. NYSE Texas officially opened for business in March and has secured a handful of companies over the past few weeks - including Trump Media & Technology Group - as its "founding" members. "The conversations we're having are incredibly positive," Martin said, adding that NYSE Texas had another double-digit dual listing lined up. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
33 minutes ago
- Yahoo
More Americans turning to weight loss drugs to shed weight
HARTFORD, Conn. (WTNH) — More Americans are turning to medical weight loss drugs to lose weight. Before you start, you may want to think about speaking with a registered dietitian nutritionist. Hartford HealthCare's Cody Krawec, a clinical nutrition manager at St. Vincent's Medical Center, joined Good Morning Connecticut at 9 a.m. to explain. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
35 minutes ago
- Yahoo
Wedgewood Pharmacy Adds GS-441524 to Its FIP Treatment Portfolio
SWEDESBORO, N.J., June 05, 2025--(BUSINESS WIRE)--Wedgewood Pharmacy today announced the availability of a GS-441524 formula, a compounded oral antiviral formulation now part of its feline infectious peritonitis (FIP) treatment capabilities. With this addition, veterinarians can now prescribe both GS-441524 and Molnupiravir for their patients, two of the most requested compounded antivirals for FIP, through a single trusted source backed by pharmacist support and FDA-registered ingredient sourcing. GS-441524 can be compounded as a 50mg/ml flavored oral oil suspension in multiple sizes, to improve compliance and ease of administration. The addition complements Wedgewood's Molnupiravir formulations, giving veterinarians access to two antivirals with distinct mechanisms of action. "FIP is one of the toughest diagnoses we face, not just clinically, but emotionally too," said Dr. Rae Hutchins, Chief Veterinary Officer at Wedgewood. "For a long time, vets had to deal with inconsistent access and quality when it came to GS-441524. Now, by offering both GS-441524 and Molnupiravir from one trusted, pharmacist-supported source, we're making it easier for veterinarians to focus on what matters most, giving their patients the best possible chance." "Having access to both GS-441524 and Molnupiravir compounded formulations through Wedgewood not only widens access to affordable FIP treatment across the US, but it also gives veterinarians the ability to easily choose and adapt treatment to best suit the needs of their patients and clients," said Nicole Jacque, co-founder of FIP Global Cats. "Having pharmacists who understand the urgency and complexity of these cases partnering with veterinarians is key to ensuring the best treatment outcomes for cats with FIP." Until recently, many veterinarians relied on fragmented or unregulated sources for GS-441524, making it difficult to ensure consistency and continuity of care. The introduction of this option through Wedgewood reflects a direct response to those challenges, providing prescribers with a trusted, quality-assured formulation from a pharmacy they can count on. The launch of GS-441524 builds on Wedgewood's long-standing role in supporting veterinarians with customized treatment solutions for complex cases. As part of its commitment to responsible compounding, the pharmacy emphasizes that its GS-441524 formulation is not approved by the FDA, has not been studied in clinical trials, and Wedgewood makes no claims of efficacy or safety. Independent third-party studies related to GS-441524 are available for veterinary reference through Wedgewood's FIP Resource Center. To learn more about GS-441524 and access educational resources, visit About WedgewoodWedgewood is the nation's largest and most trusted provider of compounded veterinary medications. Its next-generation home delivery platform, Blue Rabbit, streamlines patient care and marks a significant evolution in online pharmacy services. Together, Blue Rabbit and Wedgewood serve more than 70,000 veterinary professionals and more than one million animals annually. For more information visit About FIP Global Cats FIP Global CATS® (Community, Advocacy, Treatment, Support) is a leading organization in the fight against feline infectious peritonitis (FIP). Uniting veterinarians, researchers, and pet owners, it provides crucial support to those facing an FIP diagnosis. The organization is committed to empowering pet parents, advocating for safe, effective and affordable legal treatments, and advancing FIP research. For more information, please visit View source version on Contacts Jennifer Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
